How Long Hormone Therapy Lasts for Breast Cancer and Why Plans Run for Years

The surgery is done. The radiation appointments are finished. Then a nurse hands over a small box and mentions, almost in passing, that this part of treatment will last five years. Possibly ten. For many people that is the moment the timeline of breast cancer finally sinks in, and the first thing they type into a search bar that night is some version of how long is hormone therapy.

It is a fair question, and the answer deserves more than a number. Five years is not an arbitrary round figure. It comes from decades of trials that tracked what happens to hormone-sensitive breast cancer long after the tumor itself is gone, and it keeps getting revisited as new evidence lands.

This explainer walks through why the plan runs for years, who is usually offered it, what the first months tend to feel like, and how the decision to extend or stop is made. The one thing it will not do is make that decision for you; that stays with your care team.

How long is hormone therapy for breast cancer? The honest short answer

Five years is the anchor. Both the National Cancer Institute and the NHS describe adjuvant hormone therapy, meaning treatment given after surgery to lower the chance of the cancer returning, as a course that typically runs for at least five years. For some people the team recommends continuing to ten years, either on the same class of medicine or by switching classes partway through.

That single figure hides several different situations, and it helps to separate them early.

• After surgery for early-stage, hormone receptor-positive breast cancer: usually 5 years, extended to 10 in selected cases.
• Before surgery (called neoadjuvant therapy): commonly a few months, with the aim of shrinking the tumor so the operation can be smaller.
• For metastatic breast cancer, where the disease has spread beyond the breast and nearby lymph nodes: hormone therapy continues for as long as it is controlling the cancer and side effects remain manageable, which can be months or years.
• For risk reduction in people who have not had breast cancer but carry a high risk: usually around 5 years.

Notice what these ranges share. None of them is a promise, and none is fixed on the day treatment starts. Oncologists revisit the plan at follow-up visits, weighing the original tumor’s features, how the person is coping, and whether newer evidence has shifted the balance. Someone who begins expecting five years may be asked to consider ten; someone struggling badly may have the plan adjusted well before that.

So when people ask how long is hormone therapy, the most accurate reply is: long enough to cover the years when hormone-sensitive breast cancer is most likely to try to come back, and that window, as the next sections show, is wider than most people imagine.

What hormone therapy for breast cancer actually does inside the body

Hormone therapy is easy to confuse with the hormone replacement therapy taken for menopause, but it does the opposite job. Instead of adding hormones, it removes their influence.

Most breast cancers are hormone receptor-positive. A receptor is a protein on the surface of a cell that a hormone can attach to, a bit like a key fitting a lock. When estrogen or progesterone docks onto these receptors, the cancer cell receives a signal to grow and divide. Endocrine therapy, the term many oncologists use interchangeably with hormone therapy, is designed to jam that signal.

There are three broad ways to do it, and understanding them makes the multi-year timeline less mysterious.

• Blocking the lock. Selective estrogen receptor modulators, a drug class that includes the generic medicine tamoxifen, sit in the receptor so estrogen cannot. The hormone is still circulating; it simply cannot deliver its message to the cancer cell.
• Cutting off the supply after menopause. Once the ovaries stop producing estrogen, the body still makes small amounts using an enzyme called aromatase, found in fat, muscle and skin. Aromatase inhibitors switch off that enzyme, lowering estrogen levels further.
• Quieting the ovaries before menopause. Ovarian suppression uses medicines, or occasionally surgery, to stop the ovaries making estrogen. It is often combined with one of the other two approaches in younger patients.

None of these is chemotherapy. They do not directly kill rapidly dividing cells, and they do not usually cause hair loss. Their job is quieter: to keep any stray cancer cells that survived surgery in a starved, dormant state so they cannot form a new tumor. The catch is that those cells can wait a very long time, which is exactly why treatment is measured in years rather than weeks.

Why does hormone therapy last years instead of weeks?

Here is the fact that reframes the whole conversation. Hormone-sensitive breast cancer does not follow the pattern most people expect from cancer, where the danger is front-loaded into the first couple of years. Its recurrence risk stretches out, slowly and steadily, for two decades.

The clearest evidence comes from a pooled analysis of nearly 63,000 women with hormone receptor-positive breast cancer who had completed five years of endocrine therapy and were then followed to year 20. Recurrences kept appearing at a roughly constant rate throughout years five to twenty. By the twenty-year mark, the risk of the cancer returning at a distant site ranged from about 10 percent for the smallest, node-negative tumors to roughly 40 percent for larger tumors with several involved lymph nodes.

Think of it less like a fire that is out once the flames are gone and more like embers under ash. Surgery and radiation remove what can be seen. Hormone therapy keeps the embers from catching, and it only works while it is being taken, plus a carry-over period afterward that trials have shown persists for years.

That biology explains three things patients often find puzzling. First, why the course is so long: a treatment covering only year one would miss most of the window. Second, why some people are asked to extend to ten years: for higher-risk tumors, the later years still carry meaningful risk. Third, why finishing the course does not end follow-up: the risk does not drop to zero on the last day.

It also explains why oncologists tend to be cautious about stopping early. The medicine is not treating a symptom you can feel. It is holding a door shut on something you cannot.

Who is usually offered hormone therapy, and who is asked to wait

The single deciding factor is the tumor’s receptor status, determined by a pathologist examining the tissue removed at biopsy or surgery. If the cancer cells carry estrogen or progesterone receptors, hormone therapy is usually part of the plan. If they carry neither, the medicine has nothing to block, and it is not offered regardless of stage.

Beyond that, several situations shape who starts and when.

• Postmenopausal patients are commonly offered an aromatase inhibitor, a selective estrogen receptor modulator, or a sequence of the two.
• Premenopausal patients are usually offered a selective estrogen receptor modulator, sometimes combined with ovarian suppression when the recurrence risk is higher. Aromatase inhibitors alone do not work while the ovaries are still active.
• People receiving chemotherapy are typically asked to wait. Hormone therapy usually begins once chemotherapy is complete, because giving them together has not been shown to add benefit and can complicate side effects.
• People having radiation may start hormone therapy during or after it, depending on the team’s protocol.
• Anyone who is pregnant or trying to conceive is asked to wait, because these medicines can harm a developing pregnancy.

Some people are asked to pause rather than avoid treatment altogether: before major surgery, because of clot risk with certain classes, or while a bone density scan is arranged before starting a medicine known to thin bone.

A smaller group with very low-risk tumors may be told the expected benefit is modest and the choice is genuinely theirs. That is a legitimate conversation, not a sign of neglect. The oncology team weighs tumor size, grade, lymph node involvement, age, other health conditions and personal preference, and the recommendation reflects all of them together rather than any one number.

Signs you need hormone therapy? Why the answer is a lab report, not a symptom

People searching for signs that they need hormone therapy are usually asking one of two different questions, and it pays to untangle them.

If the question is about breast cancer, there are no bodily signs. Nothing about how a tumor feels, how large it is, or how a person feels day to day reveals whether the cancer cells carry hormone receptors. That information comes from a laboratory test called immunohistochemistry, in which a stain is applied to a thin slice of tumor tissue and a pathologist estimates what proportion of cells light up for estrogen and progesterone receptors. The result appears on the pathology report as positive or negative, often with a percentage. Your team may also check HER2, a different protein that guides a separate class of treatment.

That report, not any symptom, decides whether hormone therapy is on the table. It is worth asking to see it and having someone walk you through the receptor lines.

If the question is really about menopause, and the searcher is wondering whether hot flashes, poor sleep or mood changes mean they need hormone replacement, that is a conversation about a completely different treatment with different goals. For someone with a history of hormone receptor-positive breast cancer, it is also a conversation that needs the oncology team in the room, because adding estrogen back is generally avoided after this diagnosis.

One more distinction matters. Hormone therapy for breast cancer is not started because a person is feeling unwell and it is not expected to make them feel better. In the adjuvant setting it is given to someone who may feel completely recovered, to protect against a risk they cannot perceive. That is emotionally harder than taking a medicine for a symptom, and it is one reason the years-long course tests people’s resolve.

How long should you stay on hormone therapy: the case for 5 years versus 10

For decades, five years was simply the standard, because that is how long the original trials ran. Then researchers asked the obvious follow-up question: what if people kept going?

The largest test of that idea was the ATLAS trial, which randomly assigned nearly 13,000 women who had already completed five years of a selective estrogen receptor modulator to either stop or continue to ten years. Among those with hormone receptor-positive disease, continuing lowered the chance of recurrence between years five and fourteen from about 25 percent to about 21 percent, and lowered breast cancer mortality in that window from about 15 percent to about 12 percent. Most of that difference appeared after year ten, a delayed payoff that fits the slow-burn biology described earlier.

Trials of extended aromatase inhibitors, and of switching from one class to the other after five years, have shown broadly similar patterns: a modest additional reduction in recurrence, purchased at the cost of five more years of side effects and, with the extended selective estrogen receptor modulator group in ATLAS, a small increase in uterine cancer and blood clot risk.

The word to hold onto is modest. Extended therapy is not twice as good as five years. Its extra benefit is real but small, so the people most likely to be offered it are those whose original tumor was larger, higher grade or had spread to lymph nodes, where the absolute risk in years ten to twenty is high enough that a few percentage points matter.

For someone with a small, node-negative tumor who has struggled with joint pain or hot flashes, the same few points may not justify another five years, and a team may reasonably recommend stopping at five. Neither choice is wrong. The right length is the one that matches your risk, your tolerance and your values, decided with your oncologist rather than by a headline.

Hormone therapy duration for breast cancer at a glance

Because the same phrase covers such different clinical situations, a summary table is more useful here than another paragraph. The ranges below are typical patterns drawn from National Cancer Institute, NHS and Mayo Clinic guidance; individual plans vary, and the treating team sets the actual course.

Situation	Typical length	What usually decides the end point
After surgery, early-stage, lower recurrence risk	About 5 years	Completion of the planned course; tolerance of side effects
After surgery, early-stage, higher recurrence risk	Up to 10 years, sometimes as a sequence of two classes	Tumor size, grade, lymph node involvement; how well the first 5 years were tolerated
Premenopausal, with ovarian suppression added	Usually 5 years; extension considered case by case	Age, recurrence risk, bone health, fertility wishes
Before surgery (neoadjuvant)	Several months	Tumor shrinkage on imaging; surgical timing
Metastatic breast cancer	Ongoing, often months to years	Whether scans show the cancer is controlled; side effects
Risk reduction without a cancer diagnosis	About 5 years	Completion of the planned course; side effects

Two patterns stand out. In the adjuvant setting, the length is decided mostly in advance and then confirmed or adjusted at review. In the metastatic setting it is the reverse: nobody sets an end date, and treatment continues as long as it is doing its job, with the team switching to a different approach if the cancer begins to grow again.

A third, quieter point: the table lists years, but people live them one day at a time. A five-year course is roughly 1,800 mornings of remembering a medicine for a risk you cannot feel. Recognizing that scale is the first step to planning for it.

What the first weeks and months of hormone therapy usually look like

Unlike chemotherapy, hormone therapy rarely announces itself on day one. Most people take the first dose and feel nothing at all, which can be reassuring or oddly anticlimactic after everything that came before.

Over the first few weeks, the body notices the drop in estrogen signaling. Hot flashes are the most common early arrival, along with night sweats and sometimes disturbed sleep. Mayo Clinic and the National Cancer Institute both list these among the expected effects of every class of breast cancer hormone therapy. For people who were already through menopause, it can feel like a replay; for younger patients on ovarian suppression, it can feel like menopause arriving all at once.

By the second or third month, class-specific effects tend to emerge. Aromatase inhibitors are known for joint stiffness and aching, often worst first thing in the morning and easing with movement. Selective estrogen receptor modulators are more often linked with vaginal discharge or dryness and, less commonly, mood changes. Fatigue crosses both groups.

Around this time the care team usually schedules a check-in. This is the moment to be specific about what is happening rather than stoic. Many side effects have established management strategies, from exercise programs for joint pain to non-hormonal approaches for hot flashes, and some people do better simply by switching to a different medicine within the same class or to the other class entirely. That switch is a clinical decision, not a do-it-yourself one.

Bone health also enters the picture early. Because aromatase inhibitors lower estrogen further, they can accelerate bone thinning, so a baseline bone density scan and periodic repeats are standard. Weight-bearing exercise, adequate calcium and vitamin D intake, and not smoking are the everyday measures teams recommend alongside monitoring.

By six months, most people have found a rhythm. The side effects that remain are usually the ones that will need active management for the duration.

Does hormone therapy cause weight gain, and is it the same as HRT?

Two of the most common questions people type alongside this topic are about weight, and both are tangled up with menopause hormone replacement. It is worth pulling them apart.

Hormone therapy for breast cancer and hormone replacement therapy for menopause are opposites in mechanism. Cancer hormone therapy lowers or blocks estrogen; menopause hormone replacement adds it back. A person who has had hormone receptor-positive breast cancer is generally advised not to take estrogen-containing menopause treatment, because it could feed any remaining hormone-sensitive cells. So questions like whether you lose weight after starting HRT, or whether you ever stop HRT, belong to a different treatment and a different population.

On weight and cancer hormone therapy specifically, the evidence is less dramatic than folklore suggests. Weight gain is listed as a possible side effect of both major classes, but studies that have measured it carefully have found the average change is small, and a large share of it overlaps with the weight gain many women experience at midlife regardless of treatment. Chemotherapy, reduced activity during recovery, disturbed sleep from hot flashes, and the menopause transition itself all contribute. Isolating the medicine’s own effect is difficult.

What is clear is that weight matters for other reasons during a long course. Excess body fat produces estrogen through the aromatase enzyme, which is one reason maintaining a healthy weight is part of standard guidance after hormone receptor-positive breast cancer. Physical activity has also been shown in trials to ease aromatase inhibitor joint pain.

The practical message is not to expect a particular number on the scale, up or down, from the medicine alone. It is to treat activity and nutrition as part of the multi-year plan, and to raise any noticeable change with the care team rather than assuming it is inevitable or ignoring it.

The side effects that quietly shape how long people stay on treatment

In trials, the planned length of hormone therapy is five or ten years. In real life, a meaningful proportion of people stop earlier than planned, and studies of adherence consistently identify side effects as the leading reason. That gap is where much of the potential benefit is lost, so it deserves honest attention.

The effects most often cited are not the rare, serious ones. They are the daily, grinding ones: hot flashes that interrupt meetings and sleep, joint stiffness that makes stairs a chore, vaginal dryness that affects intimacy, and a fog of fatigue that is hard to describe to people who expected you to be back to normal. Taken together over years, they wear people down.

The serious effects are rarer but shape monitoring. Selective estrogen receptor modulators slightly raise the risk of blood clots in the legs or lungs and, in postmenopausal women, of cancer of the uterine lining. Aromatase inhibitors raise the risk of bone thinning and fractures and are associated with changes in cholesterol. MedlinePlus and Mayo Clinic list these in their patient information, and they underpin the red flags in the section on when to call your doctor.

Three points help people stay the course.

• Side effects are not a sign the medicine is failing or that the cancer is active; they are a sign the medicine is doing what it is designed to do.
• Switching between medicines within a class, or between classes, is common and can markedly change how someone feels; several trials built this switch into their design.
• Short, supervised breaks are sometimes used to test whether a symptom is truly from the medicine.

Every one of those adjustments is a clinical decision. Stopping quietly at home because the joint pain became unbearable is understandable, but telling the team first opens options that stopping alone does not.

When to stop hormone therapy: how the end of the course is decided

Ending hormone therapy is less of an event than people imagine. There is no tapering schedule for most people, no scan to confirm that the coast is clear, and no ceremony. On the agreed date, or at the follow-up visit closest to it, the oncologist confirms the course is complete and the medicine simply stops.

What leads up to that point is a review, and it usually covers four things. The original pathology: tumor size, grade, receptor levels and lymph node status, which set the baseline risk. The years already completed, and how they went. Any new evidence about extended therapy that applies to that risk group. And the person’s own wishes, including their experience of side effects and how they feel about another five years.

From that conversation come three possible outcomes. Stop at the planned point. Extend, either on the same medicine or by switching to the other class. Or, occasionally, stop earlier than planned because side effects have become unacceptable or another health condition has changed the balance.

Stopping does not mean discharge. Follow-up continues, typically with regular clinical visits and annual mammograms, because, as the twenty-year data show, recurrence risk persists after treatment ends. Some people find this stage harder than they expected: the daily medicine was a tangible act of protection, and its absence can feel like exposure. That reaction is common and worth naming to the team.

Side effects generally ease over the months after stopping, particularly hot flashes and joint symptoms, though bone density does not automatically recover and may still need monitoring. Any symptom that appears or worsens after stopping should be reported rather than assumed to be withdrawal.

The decision about when to stop hormone therapy, like the decision to start, belongs to the person and their treating team together. What the evidence provides is a framework; what the conversation provides is the answer.

What people often get wrong about how long hormone therapy lasts

Years of listening to patients reveal a handful of misunderstandings that come up again and again. Correcting them matters, because several of them lead directly to stopping early.

Myth: Hormone therapy is the same as HRT. It is the reverse. Menopause hormone replacement adds estrogen; breast cancer hormone therapy blocks or lowers it. Guidance about how long menopause HRT can safely continue does not apply here.

Myth: Being on it means the cancer is still there. In the adjuvant setting, the medicine is given precisely because there is no detectable cancer. It protects against microscopic cells that may or may not exist. Being on treatment is not evidence of disease.

Myth: Feeling well after two years means it can stop. Feeling well is the expected state. The medicine does not treat a symptom, so the absence of symptoms says nothing about whether it is still needed. Recurrence risk for hormone-sensitive cancer continues steadily for two decades.

Myth: Ten years is always better than five. Extended therapy offers a modest additional benefit that is largest for higher-risk tumors and comes with additional side-effect burden. For low-risk disease, five years may be the better-balanced choice.

Myth: Missing a dose here and there undoes everything. Occasional missed doses are common and are not thought to erase years of protection. Sustained, unreported non-adherence is the real concern. If doses are being missed regularly, tell the team rather than adjusting on your own.

Myth: Diet, supplements or natural remedies can replace it. No food, herbal product or supplement has been shown in trials to lower recurrence the way endocrine therapy does. Some supplements marketed for menopause contain plant estrogens whose safety after hormone receptor-positive breast cancer is uncertain, and they should be discussed with the team before use.

Myth: Once it ends, follow-up ends. Surveillance continues for years after the last dose.

Questions to ask your care team about the length of hormone therapy

Oncology appointments move quickly, and the questions that matter most about duration tend to surface later, at home. Bringing a short written list helps. These are the ones that experienced patients and clinicians say get the most useful answers.

• What did my pathology report show for estrogen receptor, progesterone receptor and HER2, and how do those results shape the plan?
• Which class of hormone therapy are you recommending, and why that one for me rather than the alternative?
• Is the plan five years, ten years, or five with a review? What would make you recommend extending?
• Will I switch to a different medicine partway through, and if so, when and why?
• Which side effects should I expect in the first three months, and which ones should prompt a call rather than waiting for the next visit?
• If I develop joint pain or hot flashes that affect my daily life, what options exist for managing them or changing the medicine?
• Do I need a bone density scan before starting, and how often will it be repeated?
• If I am premenopausal, how does ovarian suppression fit, and what does it mean for fertility and future pregnancy?
• What is the safest way to raise a missed dose or a decision to pause, and who do I contact?
• Which other medicines or supplements should I check with you before taking, because of interactions?
• When the course ends, what will follow-up look like and for how long?
• Is there a nurse, pharmacist or survivorship clinic I can contact between appointments?

Two habits make the answers stick. Ask whether the plan can be written down, including the intended end date and any review points, so it can be revisited without relying on memory. And bring someone along, or ask to record the conversation, because the details of a five-to-ten-year plan are rarely absorbed in one sitting.

None of these questions challenge the team’s judgment. They are the questions the team hopes you will ask.

When to call your doctor during hormone therapy

Most of what hormone therapy brings is uncomfortable rather than dangerous, and it belongs in the conversation at a scheduled visit. A small number of signs point to the rarer serious effects and should prompt a same-day call, or emergency care if they are severe. These reflect the risks listed for these medicine classes by MedlinePlus, Mayo Clinic and the National Cancer Institute.

Seek urgent or emergency care for:

• Sudden chest pain, shortness of breath, or coughing up blood, which can signal a clot in the lung.
• Pain, swelling, warmth or redness in one calf or thigh, which can signal a clot in the leg.
• Sudden weakness or numbness on one side of the body, difficulty speaking, or sudden severe headache, which can signal a stroke.
• Sudden vision changes or loss of vision.

Call your care team promptly for:

• Any vaginal bleeding after menopause, or unusual bleeding, spotting or discharge at any age, which needs evaluation of the uterine lining.
• A fall or injury followed by bone pain, given the fracture risk with some classes.
• Persistent or worsening pelvic pain or pressure.
• A new lump in either breast, the chest wall or under the arm, or new bone pain, persistent cough or unexplained weight loss that does not settle, since recurrence can present this way and warrants assessment.
• Mood changes that are frightening, persistent, or include thoughts of self-harm.
• Side effects that are making you consider stopping the medicine, so alternatives can be discussed before you do.

Keep the oncology team’s contact details, including an out-of-hours number, somewhere you can find them quickly. If you are ever unsure whether something counts, call anyway. Teams would far rather field a call about a symptom that turns out to be nothing than learn later that a person stopped treatment or ignored a warning sign because they did not want to bother anyone.

Frequently asked questions

How long should you stay on hormone therapy for breast cancer?

Usually at least five years after surgery, according to National Cancer Institute and NHS guidance, with some people advised to continue for up to ten years. The longer course is generally reserved for tumors with higher recurrence risk, such as larger size or lymph node involvement, because the additional benefit is modest and comes with extra side effects. The final length is agreed with the oncology team and reviewed at follow-up visits.

Do you ever stop hormone therapy, or is it for life?

For early-stage breast cancer treated after surgery, hormone therapy has a planned end point of five or ten years, after which it stops and follow-up continues. For metastatic breast cancer, it continues for as long as it is controlling the disease and side effects remain manageable, so there is no set end date. Stopping early because of side effects is sometimes appropriate, but it should be a decision made with the treating team.

What are the signs that you need hormone therapy?

There are no physical signs. Whether hormone therapy is suitable depends entirely on a laboratory test of tumor tissue that shows whether the cancer cells carry estrogen or progesterone receptors. If they do, the treatment can block the hormone signal that drives growth; if they do not, it has no target and is not offered. The result appears on the pathology report, which your team can walk you through.

Do you lose weight after starting HRT, and is that the same as cancer hormone therapy?

They are different treatments. Menopause hormone replacement adds estrogen; breast cancer hormone therapy blocks or lowers it. Weight change is not a reliable effect of either. For cancer hormone therapy, weight gain is listed as a possible side effect, but careful studies find the average change is small and overlaps with midlife weight gain from other causes. Any noticeable change should be raised with the care team rather than attributed automatically to the medicine.

Do you ever stop hormone replacement therapy after breast cancer?

Estrogen-containing hormone replacement is generally avoided after hormone receptor-positive breast cancer because it could stimulate any remaining hormone-sensitive cells, so most people are advised to stop it at diagnosis. Menopause symptoms are then managed with non-hormonal approaches. Anyone already taking hormone replacement who receives a breast cancer diagnosis should discuss it with their oncology team rather than stopping or continuing on their own.

Is 10 years of hormone therapy always better than 5?

No. Trials such as ATLAS show extended therapy offers a modest additional reduction in recurrence, largest for higher-risk tumors, alongside five more years of side effects and a small rise in risks such as blood clots or uterine cancer with one class. For small, low-risk tumors, the extra benefit may not outweigh the burden, and stopping at five years is a reasonable recommendation. The balance is weighed individually.

What happens if I miss doses of hormone therapy?

An occasional missed dose is common and is not thought to undo years of protection. Regularly missed doses are a different matter, because the medicine only works while it is being taken and adherence studies link gaps to reduced benefit. Rather than adjusting on your own, contact your care team or pharmacist for instructions and mention any reason, such as side effects, that is making doses hard to take.

Can I pause hormone therapy to try for a pregnancy?

Some younger patients ask about a planned interruption to conceive, and this has been studied in clinical trials in selected low-risk situations. It is not a decision to make alone, because these medicines can harm a pregnancy and the pause temporarily removes protection. The oncology team, often with a fertility specialist, can explain what the evidence shows for your circumstances and how treatment would resume afterward.

Does hormone therapy continue during chemotherapy or radiation?

Hormone therapy is usually started after chemotherapy finishes rather than alongside it, because combining them has not shown added benefit and can complicate side effects. With radiation, practice varies: some teams begin hormone therapy during radiation and others wait until it is complete. The sequence is part of the overall treatment plan and is set by the treating team based on the specific situation.

How long do side effects last after hormone therapy ends?

Many side effects, particularly hot flashes and joint stiffness, ease gradually over the months after the last dose as hormone signaling returns to the body’s baseline. Bone density lost during aromatase inhibitor treatment does not automatically recover and may still need monitoring. Any new or worsening symptom after stopping should be reported to the care team rather than assumed to be part of adjustment.

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.